Liu Jia, Hu Yanjin, Xu Yuan, Jia Yumei, Miao Li, Wang Guang
Department of Endocrinology, Beijing Chao-Yang Hospital, Capital Medical University, No. 8, Gongti South Road, Chaoyang District, Beijing 100020, China.
Int J Endocrinol. 2017;2017:9401606. doi: 10.1155/2017/9401606. Epub 2017 Nov 20.
The present study assessed the therapeutic effect of exenatide and metformin as the initial therapy on overweight/obese patients with newly diagnosed type 2 diabetes (T2D).
The prospective, nonrandomized, interventional study enrolled a total of 230 overweight or obese patients with newly diagnosed T2D who were administrated exenatide or metformin hydrochloride for 12 weeks.
224/230 patients, including 106 in the exenatide group and 118 in the metformin group, completed the 12-week treatment. Both exenatide and metformin significantly decreased the HbA1c levels in overweight/obese patients with newly diagnosed T2D (all < 0.05). The reduction in HbA1c and the proportion of patients with HbA1c < 7.0% (53 mmol/mol) were higher in the exenatide group than in the metformin group (all < 0.05). The exenatide treatment caused a greater decline in the body weight and BMI as compared to the metformin treatment (all < 0.01). The exenatide treatment ( = 0.41, < 0.01) and baseline HbA1c level ( = -0.84, < 0.01) were independent influencing factors for the decrease in HbA1c level.
For an initial therapy in overweight/obese patients with newly diagnosed T2D, exenatide causes a better glycemic control than metformin. This trial is registered with NCT03297879.
本研究评估艾塞那肽和二甲双胍作为初始治疗对新诊断的2型糖尿病（T2D）超重/肥胖患者的治疗效果。
这项前瞻性、非随机、干预性研究共纳入230例新诊断的T2D超重或肥胖患者，给予艾塞那肽或盐酸二甲双胍治疗12周。
224/230例患者完成了12周治疗，其中艾塞那肽组106例，二甲双胍组118例。艾塞那肽和二甲双胍均显著降低了新诊断的T2D超重/肥胖患者的糖化血红蛋白（HbA1c）水平（均P<0.05）。艾塞那肽组HbA1c的降低幅度及HbA1c<7.0%（53 mmol/mol）的患者比例高于二甲双胍组（均P<0.05）。与二甲双胍治疗相比，艾塞那肽治疗导致体重和体重指数（BMI）下降幅度更大（均P<0.01）。艾塞那肽治疗（β=0.41，P<0.01）和基线HbA1c水平（β=-0.84，P<0.01）是HbA1c水平降低的独立影响因素。
对于新诊断的T2D超重/肥胖患者的初始治疗，艾塞那肽比二甲双胍能更好地控制血糖。本试验已在ClinicalTrials.gov注册，注册号为NCT03297879。
